Memphasys (ASX:MEM) EBIT per Share : A$-0.00 (TTM As of Jun. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Memphasys EBIT per Share?

Memphasys's EBIT per Share for the six months ended in Jun. 2024 was A$-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.00.

During the past 5 years, the average EBIT per Share Growth Rate was -7.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was 35.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Memphasys's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Memphasys was 76.60% per year. The lowest was -26.00% per year. And the median was 43.40% per year.

ASX:MEM's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Memphasys's EBIT for the six months ended in Jun. 2024 was A$-1.94 Mil.

Memphasys EBIT per Share Historical Data

The historical data trend for Memphasys's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Memphasys EBIT per Share Chart

Memphasys Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

EBIT per Share

Get a 7-Day Free Trial

Memphasys Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

Memphasys EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Memphasys's EBIT per Share for the fiscal year that ended in Jun. 2024 is calculated as

	EBIT per Share		(A: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.025	/	2310.465
=	-0.00

Memphasys's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

	EBIT per Share		(Q: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.942	/	2310.465
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.00

Memphasys (ASX:MEM) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Memphasys EBIT per Share Related Terms

Thank you for viewing the detailed overview of Memphasys's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Memphasys Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Memphasys Ltd (ASX:MEM) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

IG7:Germany

Address

30 Richmond Road, Homebush, Sydney, NSW, AUS, 2140

Website

https://www.memphasys.com

Memphasys Ltd is an Australian-based emerging small-cap reproductive biotechnology company. It develops and commercializes novel reproduction and fertility solutions for humans and animals. Its technology includes Hydrogel and other polymer membrane technology development. The company is developing novel medical devices, diagnostics, and media with applications to assisted reproduction technologies, including IVF in humans and artificial insemination in animals.

Memphasys Headlines

No Headlines